Table of Content

1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary research respondent, By Region
2.5. Assumption & Limitation

3. Executive Summary

4. Global Pneumonia Therapeutics market Industry Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraint
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape/Recent Development
4.4. Regulatory Framework
4.5. Company Market Share Analysis, 2019
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Suppliers
4.6.2. Bargaining Power of Buyers
4.6.3. Threat of New Entrants
4.6.4. Threat of Substitutes
4.6.5. Intensity of Rivalry
4.7. Impact of COVID 19

5. Global Pneumonia Therapeutics market Overview
5.1. Market Size & Forecast by Value, 2016-2026
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.1.1. Antibacterial Drugs
5.2.1.1.1. Macrolide
5.2.1.1.2. Quinolones
5.2.1.2. Antiviral Drugs
5.2.1.3. Antifungal Drugs
5.2.2. By Age group
5.2.2.1. Pediatric
5.2.2.2. Adult
5.2.2.3. Geriatric
5.2.3. By infection
5.2.3.1. Hospital-acquired Pneumonia [HAP]
5.2.3.2. Community-acquired Pneumonia [CAP]
5.2.3.3. Ventilator-associated Pneumonia [VAP]
5.2.4. By Distribution Channel
5.2.4.1. Hospital Pharmacies
5.2.4.2. Retail Pharmacies
5.2.4.3. Online Pharmacies
5.2.5. By Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia Pacific
5.2.5.4. Latin America
5.2.5.5. Middle East & Africa

6. North America Pneumonia Therapeutics Market
6.1. Market Size & Forecast by Value, 2016-2026
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Age group
6.2.3. By infection
6.2.4. By Distribution Channel
6.2.5. By Country
6.2.5.1. United States
6.2.5.2. Canada

7. Europe Pneumonia Therapeutics market
7.1. Market Size & Forecast by Value, 2016-2026
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Age group
7.2.3. By infection
7.2.4. By Distribution Channel
7.2.5. By Country
7.2.5.1. Germany
7.2.5.2. United Kingdom
7.2.5.3. France
7.2.5.4. Italy
7.2.5.5. Spain
7.2.5.6. Rest of Europe

8. Asia Pacific Pneumonia Therapeutics Market
8.1. Market Size & Forecast by Value, 2016-2026
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Age group
8.2.3. By infection
8.2.4. By Distribution Channel
8.2.5. By Country
8.2.5.1. India
8.2.5.2. China
8.2.5.3. Japan
8.2.5.4. South Korea
8.2.5.5. Rest of Asia Pacific

9. Latin America Pneumonia Therapeutics Market
9.1. Market Size & Forecast by Value, 2016-2026
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1.1. By Drug Class
9.2.1.2. By Age group
9.2.1.3. By infection
9.2.1.4. By Distribution Channel
9.2.1.5. By Country
9.2.1.5.1. Brazil
9.2.1.5.2. Mexico
9.2.1.5.3. Rest of Latin America

10. Middle East & Africa Pneumonia Therapeutics Market
10.1. Market Size & Forecast by Value, 2016-2026
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1.1. By Drug Class
10.2.1.2. By Age group
10.2.1.3. By infection
10.2.1.4. By Distribution Channel
10.2.1.5. By Country
10.2.1.5.1. Saudi Arabia
10.2.1.5.2. UAE
10.2.1.5.3. South Africa
10.2.1.5.4. Rest of Middle East & Africa

11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
11.1. Abbott Laboratories,
11.2. Allergan,
11.3. AstraZeneca,
11.4. Bayer,
11.5. Cipla,
11.6. GlaxoSmithKline,
11.7. Lupin Pharmaceuticals,
11.8. Merck,
11.9. Mylan,
11.10. Novartis
11.11. Pfizer,
11.12. Sanofi
11.13. Other Prominent Players
* Financial details in case of unlisted companies will be available as per data availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.